Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003727831 | SCV004540398 | likely pathogenic | not provided | 2022-11-24 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Not Available"). ClinVar contains an entry for this variant (Variation ID: 689387). This missense change has been observed in individual(s) with clinical features of developmental and epileptic encephalopathy (PMID: 29961870). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces threonine, which is neutral and polar, with lysine, which is basic and polar, at codon 292 of the GABRA2 protein (p.Thr292Lys). Experimental studies have shown that this missense change affects GABRA2 function (PMID: 29961870). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
OMIM | RCV000850101 | SCV000992265 | pathogenic | Developmental and epileptic encephalopathy, 78 | 2020-11-25 | no assertion criteria provided | literature only |